Can You Take Farxiga with Hormonal Contraceptives?

Pharmacokinetic Basis: Why No Interaction Exists

Dapagliflozin is metabolized primarily through UGT1A9-mediated glucuronidation in the liver and kidney, with minimal contribution from cytochrome P450 enzymes [1]. This metabolic pathway is distinct from the CYP3A4 and CYP2C9 routes that process ethinyl estradiol and most progestins.

The FDA-approved prescribing information for Farxiga includes data from a dedicated drug interaction study in which healthy female volunteers received dapagliflozin 20 mg (twice the maximum approved dose) alongside a combined oral contraceptive containing ethinyl estradiol 30 mcg and levonorgestrel 150 mcg [2]. Results showed the geometric mean ratios for AUC and Cmax of both ethinyl estradiol and levonorgestrel remained within the standard 80-125% bioequivalence boundaries. The 90% confidence intervals confirmed no clinically relevant change in contraceptive hormone exposure.

Dapagliflozin does not inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at therapeutic concentrations [1]. It also does not induce CYP1A2, CYP2B6, or CYP3A4 based on in vitro studies. This clean CYP profile eliminates the mechanistic basis for interference with any hormonal contraceptive formulation, whether combined pills, progestin-only pills, patches, rings, or injectable depot medroxyprogesterone acetate.

Glucuronidation vs. CYP Metabolism: The Separation Principle

Understanding why this combination is safe requires examining the metabolic compartmentalization of these two drugs. Dapagliflozin's primary metabolite, dapagliflozin 3-O-glucuronide, is formed by UGT1A9 and is pharmacologically inactive [1]. This enzyme belongs to a completely different superfamily than the cytochrome P450 system.

Ethinyl estradiol undergoes hydroxylation via CYP3A4 (producing 2-hydroxy-ethinyl estradiol) and subsequent sulfation and glucuronidation [3]. The glucuronidation step for ethinyl estradiol involves UGT1A1 and UGT1A3, not UGT1A9. Even at the glucuronidation level, no substrate competition occurs between dapagliflozin and contraceptive hormones because they use different UGT isoforms.

Levonorgestrel is metabolized through CYP3A4 reduction and hydroxylation pathways [4]. Since dapagliflozin neither inhibits nor induces CYP3A4, levonorgestrel clearance remains unaffected. The same logic applies to other progestins used in contraception: norethindrone, desogestrel, drospirenone, and etonogestrel all rely on CYP3A4 or CYP2C19 for biotransformation.

P-glycoprotein and Transporter Considerations

Dapagliflozin is a substrate of P-glycoprotein (P-gp) but is not a P-gp inhibitor at clinically relevant concentrations [2]. Ethinyl estradiol is also a P-gp substrate. The theoretical concern that two P-gp substrates might compete for efflux transport has been addressed by the in vivo interaction study, which showed no meaningful pharmacokinetic changes.

The organic anion transporting polypeptides (OATP1B1, OATP1B3) involved in hepatic uptake of some drugs are not relevant here. Dapagliflozin has low affinity for these transporters, and contraceptive steroids rely primarily on passive diffusion for hepatic entry [5]. No transporter-mediated interaction mechanism has been identified in preclinical or clinical studies.

Clinical Context: Who Takes Both Drugs Together?

Women of reproductive age increasingly receive SGLT2 inhibitor prescriptions. The DAPA-HF trial (N=4,744) enrolled patients aged 18 and older with heart failure with reduced ejection fraction [6]. The DAPA-CKD trial (N=4,304) included patients with chronic kidney disease regardless of diabetes status [7]. Both trials demonstrated cardiovascular and renal benefits that extend to premenopausal women.

Type 2 diabetes prevalence among women aged 20-44 is approximately 4.7% in the United States according to CDC NHANES data [8]. Among these women, many use hormonal contraception simultaneously. The absence of a drug interaction means clinicians can prescribe dapagliflozin without modifying the contraceptive regimen or recommending backup methods.

Dr. Silvio Inzucchi, Professor of Medicine at Yale School of Medicine and co-author of the ADA/EASD consensus report on type 2 diabetes management, has stated: "SGLT2 inhibitors have a remarkably clean drug interaction profile. Unlike older diabetes medications that complicated polypharmacy, these agents can be added to virtually any existing regimen without dose adjustments" [9].

Genital Mycotic Infections: A Practical Consideration

While no pharmacokinetic interaction exists, one clinical overlap deserves attention. SGLT2 inhibitors increase urinary glucose excretion, creating a glucose-rich environment in the lower urinary tract that promotes Candida growth. In the DECLARE-TIMI 58 trial (N=17,160), genital infections occurred in 0.9% of dapagliflozin-treated patients versus 0.1% with placebo among women [10].

Hormonal contraceptives, particularly those containing estrogen, independently increase vulvovaginal candidiasis risk by promoting glycogen deposition in vaginal epithelium and enhancing Candida adhesion [11]. The combination of both medications may produce additive (though not synergistic) risk for genital yeast infections.

The Endocrine Society Clinical Practice Guideline on pharmacological management of type 2 diabetes recommends counseling patients on genital hygiene when initiating SGLT2 inhibitors [12]. For women concurrently using hormonal contraception, this counseling should be reinforced. Symptoms of vulvovaginal candidiasis (pruritus, discharge, irritation) should not be attributed to a "drug interaction" but rather to the independent pharmacodynamic effects of each medication on the genital environment.

Comparison with Other Diabetes Medications

Not all glucose-lowering agents share dapagliflozin's clean interaction profile with contraceptives. This comparison provides context for clinical decision-making.

Pioglitazone induces CYP3A4, which can reduce ethinyl estradiol exposure by up to 11% [13]. While this reduction is modest, the FDA label for pioglitazone recommends considering higher-dose contraceptive formulations or alternative methods.

Rifampin, sometimes used in tuberculosis co-infection with diabetes, is a potent CYP3A4 inducer that reduces ethinyl estradiol AUC by 64% [14]. This represents a clinically catastrophic interaction requiring non-oral contraception.

GLP-1 receptor agonists delay gastric emptying, which can reduce the rate (but not extent) of oral contraceptive absorption [15]. The FDA label for semaglutide recommends patients switch to a non-oral contraceptive or add a barrier method for 4 weeks after initiation and 4 weeks after each dose escalation.

Dapagliflozin lacks all three of these interaction mechanisms: it does not induce CYP enzymes, does not affect gastric emptying timing, and does not alter intestinal absorption. The American Diabetes Association Standards of Care 2024 do not flag any SGLT2 inhibitor-contraceptive interaction requiring clinical action [16].

Pregnancy Considerations and Contraceptive Importance

Dapagliflozin is contraindicated during the second and third trimesters of pregnancy based on animal data showing adverse renal developmental effects at exposures 1.5 times the maximum recommended human dose [2]. SGLT2 transporters play a role in fetal renal glucose handling during development. Rat pup studies demonstrated renal pelvic and tubular dilation at maternally toxic doses.

This teratogenicity concern makes reliable contraception particularly important for women of reproductive potential who take dapagliflozin. The FDA label states: "Assess pregnancy status before initiating treatment" and recommends effective contraception during therapy [2]. Knowing that dapagliflozin does not compromise hormonal contraceptive efficacy provides reassurance that standard birth control methods remain fully protective.

The European Medicines Agency (EMA) Summary of Product Characteristics for Forxiga carries similar language, advising contraception use in women of childbearing potential without specifying additional precautions beyond standard practice [17].

Non-Oral Hormonal Contraceptive Formulations

The interaction data specifically studied oral combined contraceptives. However, the mechanistic analysis extends to all hormonal delivery systems.

Transdermal patches (norelgestromin/ethinyl estradiol) bypass first-pass metabolism. Since dapagliflozin's lack of interaction is based on the absence of CYP and transporter effects rather than on gastrointestinal factors, the patch remains unaffected.

The etonogestrel vaginal ring delivers hormones through vaginal mucosa directly into systemic circulation. Dapagliflozin does not alter vaginal pH or mucosal absorption because its glucosuric effect is limited to the renal tubule [1].

Depot medroxyprogesterone acetate (DMPA) injection achieves sustained progestin levels through intramuscular depot release. No enzymatic or transporter mechanism exists by which dapagliflozin could accelerate DMPA clearance.

Levonorgestrel intrauterine devices (IUDs) achieve contraception through local endometrial effects with minimal systemic absorption. Even theoretical systemic interactions are irrelevant for this delivery method.

The etonogestrel subdermal implant (Nexplanon) relies on CYP3A4 for metabolism [18]. Since dapagliflozin does not induce this enzyme, implant efficacy is preserved throughout its 3-year lifespan.

Monitoring Recommendations

No routine monitoring for contraceptive failure is needed when combining dapagliflozin with any hormonal contraceptive. Standard clinical practice applies.

Monitor for vulvovaginal candidiasis symptoms at follow-up visits. A 2021 meta-analysis of SGLT2 inhibitor trials (pooled N=45,913) found a relative risk of 3.37 (95% CI 2.89-3.93) for genital mycotic infections in women receiving SGLT2 inhibitors compared to placebo [19]. Proactive counseling reduces patient anxiety and prevents unnecessary contraceptive method switches driven by symptom misattribution.

Check renal function (eGFR) per standard dapagliflozin monitoring protocols. SGLT2 inhibitor efficacy for glycemic control diminishes below eGFR 45 mL/min/1.73m², though cardiovascular and renal protective benefits persist at lower filtration rates per DAPA-CKD [7].

No contraceptive dose adjustment, no backup barrier method, and no additional pregnancy testing beyond routine care is required based on this drug combination alone.

The Broader SGLT2 Inhibitor Class

Empagliflozin (Jardiance) and canagliflozin (Invokana) share the same UGT1A9-predominant metabolism and lack of CYP interaction as dapagliflozin [20]. The FDA labels for all three SGLT2 inhibitors confirm no interaction with oral contraceptives. Ertugliflozin (Steglatro), sotagliflozin (Inpefa), and bexagliflozin (Brenzavvy) likewise lack CYP-mediated interactions with contraceptive hormones.

This class-wide safety profile reflects the fundamental pharmacologic design of SGLT2 inhibitors: they act on a renal tubular sodium-glucose co-transporter, are cleared primarily by glucuronidation, and do not meaningfully engage the hepatic CYP system that processes most steroid hormones. Women prescribed any SGLT2 inhibitor can continue their chosen contraceptive method without modification.

The 2024 ADA/EASD Consensus Report on type 2 diabetes management positions SGLT2 inhibitors as first-line add-on therapy for patients with established cardiovascular disease, heart failure, or CKD [16]. As these indications expand prescribing to younger populations, the confirmed absence of contraceptive interactions becomes increasingly relevant to everyday clinical practice.